Showing 241-250 of 10274 results for "".
Let's Talk about YouTube and why your Practice should have one
https://practicaldermatology.com/topics/practice-management/let-s-talk-about-youtube-and-why-your-practice-should-have-one/19116/Any form of healthcare, dental and veterinarian practice should have a YouTube account. It is known that people prefer to watch a video to learn and understand something, rather than read an article or look at a picture. YouTube gives your practice the chance to educate your patients or clients.The State of AI in Dermatology
https://practicaldermatology.com/issues/january-february-2025/the-state-of-ai-in-dermatology/32927/The term “artificial intelligence” (AI) has been inescapable since OpenAI released ChatGPT to the public in November 2022.Starting a Systemic Therapy in Atopic Dermatitis or Psoriasis
https://practicaldermatology.com/series/pa-perspectives/Starting-a-Systemic-Therapy-in-Atopic-Dermatitis-or-Psoriasis/26644/In this video, Andrew Mastro, MS, PA-C, a board-certified physician assistant (PA) at the Illinois Dermatology Institute in Chicago, discusses how to talk to patients about starting a systemic therapy in atopic dermatitis or psoriasis; how to keep the conversation to 7 minutes; and the importance ofPart 1, 1726 nm lasers: Five dermatologists discuss the laser’s benefits and drawbacks for treating acne and other skin conditions
https://practicaldermatology.com/series/scientifically-speaking/1726-nm-lasers-five-dermatologists-discuss-the-lasers-benefits-and-drawbacks-for-treating-acne-and-other-skin-conditions/24339/Chapter 1 of 7: David Goldberg, MD, from New York, Emil Tanghetti, MD, from Sacramento, Jordan Wang, MD, from Philadelphia and New York and Naz Saedi, MD, from Philadelphia talk about how they have brought in the new 1726 nm wavelength lasers into their practices, what skin conditions it is most benFirst Medication for Severe Frostbite; Biosimilar to Humira with Interchangeability Status Approved; Two Late-Stage AD Candidates Advance
https://practicaldermatology.com/series/dermwire-tv/first-medication-for-severe-frostbite-biosimilar-to-humira-with-interchangeability-status-approved-two-late-stage-ad-candidates-advance/20267/In this episode of DermWireTV, the first medication to treat severe frostbite is approved by the FDA; the first high-concentration biosimilar to Humira with interchangeability status will soon be available in the US; and two companies with late-stage atopic dermatitis candidates provide key updates.DermWireTV: Zoryve Approved; New SDPA President; Project Determi-Nation; Stelara for Pediatric PsA
https://practicaldermatology.com/topics/psoriasis/dermwiretv-zoryve-approved-new-sdpa-president-project-determi-nation-stelara-for-pediatric-psa/20115/FDA has approved Zoryve from Arcutis Biotherapeutics for the treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age or older. The novel formulation of roflumilast cream 0.3% is indicated for once-daily application. Stelara (ustekinumab) from Janssen is now approveDermWireTV: Vtama Approved; Monkey Pox; AbbVie Scholarship; LRP Pride in Dermatology
https://practicaldermatology.com/topics/psoriasis/dermwiretv-vtama-approved-monkey-pox-abbvie-scholarship-lrp-pride-in-dermatology/20097/Vtama (tapinarof) cream 1% from Dermavant is approved for the treatment of psoriasis in adults. Tapinarof is an aryl hydrocarbon receptor agonist. As a public health service, VisualDx is offering pictures of monkey pox and disease information to support clinical decision-making. Forty-five scholarshManaging Advanced Skin Cancers
https://practicaldermatology.com/conferences/aad-2021/managing-advanced-skin-cancers/19920/Treatment of advanced NMSC can be a challenge, but therapeutic options continue to expand. Todd Schlesinger, MD discusses real-world use of hedgehog inhibitors—including modified regimens and adjuvant use—and PD-1 inhibitors for advanced disease.Scientifically Speaking: Applying Energy-Based Devices Across Skin Tones
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-applying-energy-based-devices-across-skin-tones/19895/With advancements in technology and a patient-focused approach to treatment, it's possible to safely and effectively apply energy-based devices to a range of skin concerns in patients with darker skin. Host Joel L. Cohen, MD discusses treatment strategies for melasma, acne, PFB, scarring and more wiILUMYA SUPPORT™ patient access for commercial and Medicare Part B patients
https://practicaldermatology.com/topics/psoriasis/ilumya-support-patient-access-for-commercial-and-medicare-part-b-patients/19860/ILUMYA SUPPORT™ offers comprehensive programs and services to help patients start and stay on therapy with ILUMYA™. Learn about the three main patient access programs offered by ILUMYA SUPPORT™: the Early Access Program, the Co-pay Program, and the Patient Assistance Program. ILUMYA™ is reimbursed u